Sanofi Rare Blood Disorders Home

Our rare blood disorder treatments

We launched the first extended half-life therapies for people with hemophilia A and B.
We launched the first and only FDA approved treatment for adults with acquired thrombotic thrombocytopenic purpura (aTTP).
We pioneered the first and only FDA approved treatment for cold agglutinin disease (CAD) .

Learn more about our therapies for patients living with rare blood disorders

INDICATION
ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.
LEARN MORE
INDICATION
ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital Factor IX deficiency. Your healthcare provider may give you ALPROLIX when you have surgery.
LEARN MORE
INDICATION
What is CABLIVI?
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
LEARN MORE
INDICATION
ENJAYMO is a prescription medicine used to decrease the need for red blood cell transfusion due to the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).
It is not known if ENJAYMO is safe and effective in children.
LEARN MORE

This site is intended for U.S. residents only.


© 2022 Genzyme Corporation. All rights reserved.

Sanofi is a registered trademark of Sanofi or an affiliate.
All other trademarks are the property of their respective owners.

MAT-US-2107338 v3.0 09/2022